A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Clinical trial NCT06215118 · RECRUITING

Trial details

NCT number: NCT06215118
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2024-02-20
Primary completion: 2027-04-10
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.